Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chattem R&D

This article was originally published in The Tan Sheet

Executive Summary

Consumer products manufacturer will break ground for $2 mil., 10,000 sq. ft. research and development facility in Chattanooga, Tenn. in February. Slated for completion by end of calendar year, facility will be dedicated to creating line extensions for existing products, President & Chief Operating Officer Alec Taylor says. Gold Bond sales are expected to be $40 mil.-$42 mil. in FY 2002, and pHisoderm annual sales are expected in $15 mil.-$17 mil. range, Taylor reports during 1Chattem's presentation at Banc of America Securities conference Jan. 10...

You may also be interested in...

Chattem R&D

Mid-November completion of firm's $2 mil., 10,000 sq. ft. R&D facility in Chattanooga, Tenn. was about three weeks ahead of schedule, Chattem says (1"The Tan Sheet" Jan. 20, 2003, In Brief). In line with increased R&D efforts over the past two years, the firm is set to launch BullFrog Mosquito Coast, which combines sun screen with insect repellent and is designed to last six to eight hours (2"The Tan Sheet" Sept. 22, 2003, p. 4)...

Chattem Dexatrim, pHisoderm, Icy Hot Extensions Shipping In Coming Months

Chattem is gearing up to launch a slew of product line extensions in the next few months as its decision to increase its investment in R&D over the past two years begins to pay dividends

US High Court Punts On ‘Objective Falsity’ FCA Standard

Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts